February 10, 2005 -- Although the broad market climbed on Thursday, biotech added to its losses, making it a clean sweep so far this week: the Centient Biotech 200 has put in four straight down days. Following yesterday’s dramatic 2.9% drop, the Centient Biotech 200 sank another 1.44% in today’s session. We look at a significant setback for British biotech Shire Pharma, which was asked to withdraw Adderall XR from the Canadian market (can the US be next?), a bid for Peninsula Pharma, just as it was about to come public, good news on a narcolepsy drug from Cephalon, a secondary offering from recent IPO Cotherix, plus earnings results from Immtech and Advancis...
